OncLive TV

David Polsky, MD, PhD, discusses the use of circulating tumor DNA (ctDNA) in the COMBI-d trial on melanoma.

Debu Tripathy, MD, professor and chairman, Department of Breast Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses known elements of COVID-19.

Nikhil C. Munshi, MD, director of Basic and Correlative Science, Jerome Lipper Multiple Myeloma Center, Kraft Family Chair, senior physician, Dana-Farber Cancer Institute, and professor of medicine, Harvard Medical School, discusses ways to test for minimal residual disease (MRD) in multiple myeloma.

Shaji K. Kumar, MD, professor of medicine, Mayo Clinic, discusses ongoing research in multiple myeloma.

Andrew J. Armstrong, MD, discusses the use of circulating tumor cell to detect chromosomal instability in men with metastatic castration-resistant prostate cancer.

Dimitrios Tzachanis, MD, PhD, discusses research regarding post–CAR T-cell therapy progression in lymphoma.

Gopa Iyer, MD, discusses investigational FGFR inhibitors in metastatic urothelial carcinoma.

Shella Saint Fleur-Lominy, MD, PhD, discusses the role of transplant in myeloproliferative neoplasms.

Anis Hamid, MBBS, discusses the hypothesis of predictive biomarkers for newly diagnosed metastatic hormone sensitive prostate cancer.

Andrew J. Armstrong, MD, discusses the utility of AR-V7 as a biomarker in prostate cancer.

Jonathan Mizrahi, MD, discusses the goal of the phase III COMMIT trial in mismatch repair deficient colorectal cancer.

Adam M. Brufsky, MD, PhD, discusses case ascertainment bias regarding the coronavirus 2019.

Jens Hillengass, MD, discusses available imaging modalities in multiple myeloma.

Gregory A. Otterson, MD, discusses targetable biomarkers in non–small cell lung cancer.

Parameswaran Hari, MD, MRCP, discusses misconceptions regarding allogeneic stem cell transplant in multiple myeloma.

Lynette M. Sholl, MD, discusses the challenges faced with the use of tissue biopsy to test for biomarkers in lung cancer.

Ayad Hamdan, MD, hematologist and associate professor of medicine at Moores Cancer Center at the University of California, San Diego, discusses the potential use of nivolumab (Opdivo) and brentuximab vedotin (Adcetris) in patients with advanced-stage classical Hodgkin lymphoma.

Leonard G. Gomella, MD, professor, chair of the Department of Urology, and director of the Sidney Kimmel Cancer Center Network, of Thomas Jefferson University Hospital, discusses the evolution of androgen receptor (AR) inhibitors in prostate cancer.

Aaron Gerds, MD, assistant professor of medicine in the Hematology and Medical Oncology Department at the Cleveland Clinic Taussig Cancer Institute, discusses the design and safety analysis of a phase II trial of luspatercept in patients with myelofibrosis-associated anemia.

Patrick I. Borgen, MD, discusses what is currently known about coronavirus 2019 and unanswered questions that still need to be addressed.

Syed Rizvi, MD, discusses the 4-year follow-up data from the ECHELON-1 trial in Hodgkin lymphoma.

Aaron Goodman, MD, discusses the role of PD-1 inhibitors in T-cell lymphomas.

Shella Saint Fleur-Lominy, MD, PhD, an assistant professor in the Department of Medicine at NYU Langone Health

Phat Le, MD, assistant professor, Department of General Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses treatment approaches for patients with oligometastatic colorectal cancer (CRC).

Neeraj Agarwal, MD, discusses the impact of the TITAN trial in metastatic castration-sensitive prostate cancer.

Wolfgang Fendler, MD, discusses the impact of 68Ga-PSMA-11 PET imaging on the clinical management of patients with prostate cancer.

Julie N. Graff, MD, discusses the safety profile of pembrolizumab plus enzalutamide in patients with metastatic castration-resistant prostate cancer.

Petros Grivas, MD, PhD, discusses PARP inhibition in patients with germline and somatic DNA damage repair-mutated metastatic castration-resistant prostate cancer.

Matthew T. Campbell, MD, MS, shares ways to prevent the spread of coronavirus 2019.

Eugene B. Cone, MD, urologist, Massachusetts General Hospital, discusses the cardiac toxicity associated with gonadotropin-releasing hormone (GnRH) agonists in prostate cancer.